Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



How do MS patients define value?

(Source: Real Endpoints, LLC, January 2017)

There are crucial conversations occurring in the health care system about how value is defined. To explore how MS patients, providers and payers view value, Real Endpoints conducted research that found significant variability in treatment preferences among MS patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians.

It is widely acknowledged that patients with MS are different in terms of clinical needs, preferences and treatment goals. For MS patients, providing greater opportunity for successful management of the disease and its progression requires the availability of a broad range of therapeutic alternatives. Often, a treatment option that is effective and has few side effects in one MS patient may produce the opposite result in another due to the diverse nature of the disease. Additionally, different patients may require different treatments depending on their preferences or treatment goals – some patients may place more weight on slowing disease progression, while others may be concerned about safety and side effect profiles. Fortunately, as a result of treatment advances over the past several decades, a range of options are now available to meet the wide variety of needs of people with MS.

The variability in treatment needs and preferences among MS patients found in Real Endpoint’s research is also why population-level judgements of an MS treatment’s value, like the recent value assessment conducted by the Institute for Clinical and Economic Review (ICER), often fail to capture the true importance of these medicines to patients. ICER’s payer-centric value assessment also doesn’t capture significant differences in what patients value in MS treatments compared to what payers value in how MS patients are treated. If misused by payers and policymakers, ICER’s assessment could also impede successful management of MS by limiting patient and provider choice, which is critical to managing and slowing progression of the disease.

Key findings from Real Endpoints’ research include:
  • MS patients define value differently than payers and physicians. Patients ascribe highest value to a medicine’s effect on MS symptoms (such as fatigue and walking difficulty) relative to a medicine’s efficacy. On the other hand, payers and physicians are more concerned with disease progression, effect on relapse rate and effect on severity of relapses.
  • Patients are more concerned about a medicine’s safety characteristics (e.g., severity of side effects, interactions with other medications) than payers or physicians. Unfortunately, population-level judgements of value do not always align with the prioritization of patient preferences found in Real Endpoint’s research. Stakeholders who commented on ICER’s MS report noted that ICER emphasized efficacy over safety in its assessment.
  • Patients are more concerned with out-of-pocket costs than payers, who are primarily concerned about the medicine’s effect on health care services needed to treat MS. ICER’s assessment focuses on the cost-effectiveness and short-term budget impact of an MS treatment. While this information is useful to payers, it fails to acknowledge the costs that matter to patients.

Story Source: The above story is based on materials provided by PHRMA
Note: Materials may be edited for content and length

Go to Newer News Go to Older News